Alivio Therapeutics, Inc

Relay Therapeutics is a biotechnology company based in Cambridge, MA, specializing in motion-based drug design. With a team of experts and their innovative Dynamo platform, they integrate various tools to develop groundbreaking therapies for patients. Their scientific approach and pipeline of publications demonstrate their commitment to advancing the field of drug discovery. As a leader in the industry, Relay Therapeutics attracts investors and media attention, while also offering rewarding career opportunities. Their dedication to patient well-being is evident through their engagement in clinical trials and commitment to responsible practices. With a focus on collaboration and business development, Relay Therapeutics is poised to make significant contributions to the healthcare sector.Generated from the website

Arkuda is comprised of passionate and experienced team members who are dedicated to improving the lives of people affected by neurodegenerative disease. Armed with deep expertise in biology and the ab

Morphic Therapeutic Inc is a pioneering biopharmaceutical company based in Waltham, MA, specializing in the development of oral integrin medicines. Leveraging their extensive expertise in integrin biology, they aim to transform treatment paradigms for patients across multiple therapeutic areas, including autoimmune diseases, fibrosis diseases, and cancer. Their lead candidate, MORF-057, is a highly specific inhibitor of 4 7 currently in Phase 2 for inflammatory bowel disease (IBD). With a pipeline that encompasses both novel and highly validated targets, Morphic Therapeutic is committed to drugging integrins through small molecules to address unmet medical needs. They have also established a research partnership with Janssen to discover inhibitors of undisclosed integrin targets, expanding their knowledge of integrin biology into modalities beyond small molecules. Additionally, Morphic is actively developing small molecule inhibitors for the treatment of pulmonary arterial hypertension (PAH), solid tumors, and other indications, utilizing their MInT Platform to create therapeutically relevant compounds with enhanced attributes.Generated from the website